Enzalutamid (Xtandi^®) – nová šance pro pacienty s kastračně refrakterním karcinomem prostaty

Česká verzia

Authors: J. Tomášek
Authors place of work: Klinika komplexní onkologické péče LF MU a Masarykův onkologický ústav, Brno
Published in the journal: Klin Onkol 2014; 27(1): 69-70
Category: Oncology Highlights

Summary

This actuality was supported by Astellas.

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
19. 1. 2014

Zdroje

1. Scher HI, Fizazi K, Saad F et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187– 1197.

2. Fleming MT. Long‑term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. Prezentováno na ASCO- GU 2013.

3. De Bono J, Fizazi K, Shore N et al. Assessing the impact of prior treatments on the efficacy of enzalutamide (ENZ): A subanalysis of the phase 3 AFFIRM trial. Prezentováno na ESMO 2013, poster 2862.

4. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324(5928): 787– 790.

5. Hu R, Denmeade SR, Luo L. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab 2010; 5(5): 753– 764.

6. ClinicalTrials.gov [homepage on the internet]. Available from: http:/ / www.clinicaltrials.gov/ ct2/ show/ NCT01889238?term=enzalutamide+and+breast&rank=3